Korean J Gastroenterol.  2010 Oct;56(4):268-270. 10.4166/kjg.2010.56.4.268.

Risk Factors of Peptic Ulcer Disease in Korea

• Nam HS
• Kim GH

• KMID: 1718365
• DOI: http://doi.org/10.4166/kjg.2010.56.4.268

Abstract

No abstract available.

MeSH Terms

Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
Helicobacter Infections/complications/drug therapy
Helicobacter pylori
Humans
Peptic Ulcer/drug therapy/*etiology
Recurrence
Republic of Korea
Risk Factors
Smoking

Reference

1. Nomura A, Stemmermann GN, Chyou PH, Perez-Perez GI, Blaser MJ. Helicobacter pylori infection and the risk for duodenal and gastric ulceration. Ann Intern Med. 1994; 120:977–981.

2. Hawkey CJ. Non-steroidal anti-inflammatory drugs and peptic ulcers. BMJ. 1990; 300:278–284.

3. Kurata JH, Nogawa AN. Meta-analysis of risk factors for peptic ulcer. Nonsteroidal antiinflammatory drugs, Helicobacter pylori, and smoking. J Clin Gastroenterol. 1997; 24:2–17.

4. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in pep-tic-ulcer disease: a metaanalysis. Lancet. 2002; 359:14–22.

5. Kim JJ, Kim N, Lee BH, et al. Risk factors for development and recurrence of peptic ulcer disease. Korean J Gastroenterol. 2010; 56:220–228.

6. Hopkins RJ, Girardi LS, Turney EA. Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review. Gastroenterology. 1996; 110:1244–1252.

7. Dupas JL, Corallo J, Helberz T, Zaï m M. Acid suppression therapy is not required after one-week anti-Helicobacter pylori triple therapy for duodenal ulcer healing. Gastroenterol Clin Biol. 2000; 24:638–643.

8. Goh KL, Navaratnam P, Peh SC, et al. Helicobacter pylori eradication with short-term therapy leads to duodenal ulcer healing without the need for continued acid suppression therapy. Eur J Gastroenterol Hepatol. 1996; 8:421–423.

9. Kim N, Lim SH, Lee KH, Jung HC, Song IS, Kim CY. Helicobacter pylori reinfection rate and duodenal ulcer recurrence in Korea. J Clin Gastroenterol. 1998; 27:321–326.

10. Hong SJ, Eun SH, Jung JS, et al. Longterm effect after Helicobacter pylori eradication in patients with peptic ulcer disease: A retrospective study. Korean J Med. 2002; 63:23–28.

11. Graham DY, Agrawal NM, Roth SH. Prevention of NSAID-induced gastric ulcer with misoprostol: multicentre, double-blind, placebo-controlled trial. Lancet. 1988; 2:12771280.

12. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR study Group. N Engl J Med. 2000; 343:1520–1528.

13. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med. 1999; 340:1888–1899.

14. Cryer B, Feldman M. Effects of very low dose daily, longterm aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans. Gastroenterology. 1999; 117:17–25.

15. Hawkey CJ, Karrasch JA, Szczepañski L, et al. Omeprazole compared with misoprostol for ulcers associated with non-steroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med. 1998; 338:727–734.